Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight

Retatrutide, a subcutaneous triple hormone receptor agonist now in phase 3 trials, is highlighted as a potential game changer versus Novo Nordisk's Wegovy pill. The piece argues Foundayo (orforglipron) and retatrutide could materially alter competitive dynamics and market share in obesity/weight-loss therapeutics if late‑stage results validate superiority, which would likely re-rate incumbents in the sector.

Analysis

Retatrutide, a subcutaneous triple hormone receptor agonist now in phase 3 trials, is highlighted as a potential game changer versus Novo Nordisk's Wegovy pill. The piece argues Foundayo (orforglipron) and retatrutide could materially alter competitive dynamics and market share in obesity/weight-loss therapeutics if late‑stage results validate superiority, which would likely re-rate incumbents in the sector.